Invention Grant
- Patent Title: Hepatitis B immunization regimen and compositions
-
Application No.: US16772194Application Date: 2018-12-14
-
Publication No.: US11957749B2Publication Date: 2024-04-16
- Inventor: Virginia Ammendola , Babak Bayat , Clarisse Lorin , Ventzislav Bojidarov Vassilev , Alessandra Vitelli
- Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
- Applicant Address: BE Rixensart
- Assignee: GlaxoSmithKline Biologicals SA
- Current Assignee: GlaxoSmithKline Biologicals SA
- Current Assignee Address: BE
- Agent Hao Yin
- Priority: GB 21069 2017.12.15
- International Application: PCT/EP2018/085086 2018.12.14
- International Announcement: WO2019/115817A 2019.06.20
- Date entered country: 2020-06-12
- Main IPC: A61K39/29
- IPC: A61K39/29 ; A61K39/39 ; A61P31/20 ; C07K14/005 ; C12N7/00 ; A61K39/00
Abstract:
The present invention relates to immunogenic compositions and combinations thereof which may find use in immunisation regimens for the treatment of chronic hepatitis B. An immunogenic composition comprises a replication-defective chimpanzee adenoviral (ChAd) vector comprising polynucleotides encoding HBs, HBc human invariant chain (hIi) fused to the HBc. Another immunogenic composition comprises a Modified Vaccinia Virus Ankara (MVA) vector comprising polynucleotides encoding HBs and HBc. Another immunogenic composition comprises recombinant HBs, C-terminal truncated recombinant HBc and an adjuvant containing MPL and QS-21.
Public/Granted literature
- US20210154290A1 HEPATITIS B IMMUNISATION REGIMEN AND COMPOSITIONS Public/Granted day:2021-05-27
Information query
